Conference Reports for NATAP

Back

DDW Digestive Disease Week May 21-24, 2006, Los Angeles     Consensus IFN vs Pegasys for 72 Wks in Peg/RBV Relapsers - (06/12/06)   Consensus IFN for Peg/RBV Nonresponders in Germany - (06/12/06)   Hi-Dose Consensus IFN in Prior Peg/RBV Users - (06/12/06)   Consensus Interferon in Peg/RBV Relapsers & Nonresponders in Dallas: 48 weeks end of treatment viral response - (06/12/06)   The Impact of Growth Factors on Pegylated Interferon alfa-2b and Ribavirin Dose Reduction in Patients Treated for Genotype 1 Chronic Hepatitis C - (06/06/06)   Preclinical Characteristics of ITMN-191, an Orally Active Inhibitor of the HCV NS3/4A Protease Nominated for Preclinical Development - (06/06/06)   Pharmacokinetic Analysis and Liver Concentrations of a Series of Macrocyclic Peptidomimetic Inhibitors of HCV NS3/4A Protease: Identification of ITMN-191, a Potent NS3/4A Protease Inhibitor with High Liver Exposure Across Multiple Species - (06/06/06)   Growth Factors Versus Dose Reduction for Pegylated Interferon alfa-2b and Ribavirin-Associated Neutropenia and Anemia in HIV/HCV Co-Infected Patients - (06/06/06)   The Effect of Liver Fibrosis and Cirrhosis on SVR in 4913 Patients With Hepatitis C: Results From The WIN-R Trial - (06/05/06)   Affect of Viral Load on SVR Rates to PegIntron/RBV in Genotype 1 Patients in WIN-R Study - (06/05/06)   Differences In Treatment Outcome To Antiviral Therapy Based On Genotype And Viral Load In Hepatitis C Genotypes 2 And 3 In The WIN-R Trial - (06/02/06)   Safety and Efficacy of Adefovir Dipivoxil in Patients with Lamivudine-Resistant Chronic HBV Undergoing Liver Transplantation - (05/26/06)   A COMPARATIVE TRIAL OF TELBIVUDINE AND ADEFOVIR DIPIVOXIL FOR TREATMENT OF HBeAg-POSITIVE, COMPENSATED CHRONIC HEPATITIS B: 24 WEEK RESULTS - (05/26/06)   Predictive Factors for Exacerbation of Hepatitis B After Discontinuation of Oral Therapy in HBeAg-Negative Patients - (05/26/06)   Entecavir 96 Weeks in Lamivudine-Refractory HBeAg(+): efficacy, safety, resistance - (05/26/06)   NM283 + Peg: differences in response between treatment naives & nonresponders; dose reductions for safety concerns - (05/26/06)   HCV-796, new HCV non-nucleoside- 14 day study - (05/26/06)   "Week 12 Antiviral Activity of Higher Doses of albumin interferon alfa-2b (Albuferon) Combined with Ribavirin in Non-responders to Prior Interferon Based Therapy for Chronic HCV-Infection" - (05/25/06)   Entecavir (ETV) Demonstrates Consistent Responses Throughout Baseline Disease and Demographic Subgroups for the Treatment of Lamivudine-Refractory (LVD-ref) HBeAg(+) Patients with Chronic Hepatitis B - (05/25/06)   Final Analysis of Virological Outcomes and Resistance During 5 Years of adefovir Dipivoxil Monotherapy in HBeAg-Negative Patients - (05/25/06)   96-Week Viral Suppression Data From Two Studies Presented For BARACLUDE (entecavir) In Chronically-Infected Hepatitis B Patients - (05/24/06)   Results from a Cost-Effectiveness Study Demonstrate Positive Economic Impact with PEGASYS Treatment - (05/24/06)   G-CSF is safe and improves adherence and SVR in HCV patients with genotype 1 who develop Peg-IFNa-2b related severe neutropenia - (05/24/06)   African-Americans' response to Interferon: preliminary results from Virahep C Study - (05/24/06)   VX-950 HCV Protease Inhibitor + Pegasys/RBV: 28 days study results in treatment-naive - (05/24/06)   ViroPharma Announces Presentation of HCV-796 Phase 1b Data at Digestive Disease Week - (05/23/06)   HCV Protease ITMN 191, In Vitro Resistance - - (05/23/06)   High Dose Albuferon -early data - (05/23/06)   Hepatitis Patients at Risk for Accidental Acetaminophen Toxicity - (05/23/06)   Reliable early prediction of viral relapse by detection of minimal residual hepatitis C viremia at treatment week 12 with Sensitive HCV Viral load Test - (05/22/06)   High Prevalence of Hepatitis C Virus Infection Among Russian Immigrants in the New York City Metropolitan Area: Results of A Community-Based Screening Program - (05/22/06)   Noninvasive Biomarker Test for Fatty Liver - (05/22/06)   Researchers Report Results for 28-day Phase II Study of VX-950 in Combination with Pegylated Interferon and Ribavirin in Hepatitis C Patients - (05/22/06)   The prevalence of metabolic syndrome (53%) in veterans with chronic hepatitis C virus - (05/22/06)